Salix Supports CMS Announcement of First ICD-10 Code for Hepatic Encephalopathy (HE)


CMS releases new specific ICD-10 K76.82 code for HE

LAVAL, QC, August 10, 2022 /PRNewswire/ — Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) and its gastroenterology business, Salix Pharmaceuticals (“Salix”), one of the world’s largest specialty pharmaceutical companies committed to the prevention and treatment of gastrointestinal (GI) and liver diseases and disorders, today announced its support for the release of a new Centers for Medicare & Medicaid Services (CMS) specific ICD-10 code for the hepatic encephalopathy (HE) growth-based incidence of chronic liver disease in the United States.

About 4.5 million adults in the United States suffer from chronic liver disease1. As chronic liver disease progresses to decompensated cirrhosis, patients may develop comorbid conditions such as portal hypertension, ascites, and hepatic encephalopathy. Up to 80% of people with cirrhosis may develop some form of HE2. HE is also an important factor in hospitalizations and readmissions in patients with decompensated cirrhosis3.

The new diagnostic code K76.82 for patients with HE, a complication of cirrhosis, is based on the International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) and announced by CMS as efficient October 1, 2022.

The HE condition can be misdiagnosed, and the availability of this new ICD-10 code will help healthcare providers properly document the diagnosis of these patients and thus advance efforts to ensure their clinical management is appropriate.

To learn more about the Federal Register announcement, please visit here.

About Salix
Salix Pharmaceuticals is one of the world’s largest specialty pharmaceutical companies committed to the prevention and treatment of gastrointestinal (GI) and liver diseases and disorders. For more than 30 years, Salix has licensed, developed and marketed innovative products to improve the lives of patients and arm healthcare providers with life-changing solutions for many chronic and debilitating diseases. Salix currently markets its product line to US healthcare providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists and primary care. Salix is ​​headquartered in Bridgewater, New Jersey. For more information about Salix, visit and connect with us at Twitter and LinkedIn.

About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a diversified global pharmaceutical company whose mission is to improve people’s lives through our healthcare products. We develop, manufacture and market a range of products primarily in the areas of gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our participation of approximately 90% in Bausch + Lomb Corporation. With our leading sustainable brands, we deliver on our commitments by building an innovative company dedicated to advancing global health. For more information, visit and connect with us on Twitter and LinkedIn.

Forward-looking statements
This press release may contain forward-looking statements about Bausch Health, which can generally be identified by the use of the words “anticipates”, “hopes”, “expects”, “intends”, “expects”. , “should”, “could”, “would”, “may”, “believe”, “subject to”, and variations or similar expressions. These statements are based on management’s current expectations and beliefs and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, actual results are subject to other risks and uncertainties that relate more broadly to Bausch’s overall business Health, including those more fully described in Bausch Health’s filings with the United States Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein. i by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual results, except as required by law.


1. Centers for Disease Control and Prevention. Chronic liver disease and cirrhosis. Accessed April 19, 2022.
2. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715-735.
3. Chirapongsathorn S C, Krittanawong C, Enders FT, et al. Analysis of the incidence and costs of hospitalization and 30-day readmission in patients with cirrhosis. Common Hepatol. 2018;2(2):188-198. Published January 18, 2018. doi:10.1002/hep4.1137

©2022 Salix Pharmaceuticals or its affiliates.

SOURCE Bausch Health Companies Inc.


Comments are closed.